Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists ...

Background: Clear cell renal cell carcinoma (ccRCC) is a highly aggressive renal cancer subtype and lacks highly precise individualized treatment options. Thus, we used a novel computational framework ...

Papillary renal cell carcinoma is a type of kidney cancer that starts in the kidneys' tubules. Read about the symptoms, diagnosis, treatment, and outlook.